TDP-43 dysregulation and neuromuscular junction disruption in amyotrophic lateral sclerosis

Transl Neurodegener. 2022 Dec 27;11(1):56. doi: 10.1186/s40035-022-00331-z.

Abstract

Amyotrophic lateral sclerosis (ALS) is a disease characterized by upper and lower motor neuron (MN) loss with a signature feature of cytoplasmic aggregates containing TDP-43, which are detected in nearly all patients. Mutations in the gene that encodes TDP-43 (TARBDP) are known to result in both familial and sporadic ALS. In ALS, disruption of neuromuscular junctions (NMJs) constitutes a critical event in disease pathogenesis, leading to denervation atrophy, motor impairments and disability. Morphological defects and impaired synaptic transmission at NMJs have been reported in several TDP-43 animal models and in vitro, linking TDP-43 dysregulation to the loss of NMJ integrity in ALS. Through the lens of the dying-back and dying-forward hypotheses of ALS, this review discusses the roles of TDP-43 related to synaptic function, with a focus on the potential molecular mechanisms occurring within MNs, skeletal muscles and glial cells that may contribute to NMJ disruption in ALS.

Keywords: Amyotrophic lateral sclerosis; Denervation; Dying-back; Dying-forward; Neuromuscular junction; TDP-43.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amyotrophic Lateral Sclerosis* / pathology
  • Animals
  • DNA-Binding Proteins / genetics
  • DNA-Binding Proteins / metabolism
  • Motor Neurons / pathology
  • Neuromuscular Junction / metabolism
  • Neuromuscular Junction / pathology
  • Synaptic Transmission

Substances

  • DNA-Binding Proteins

Grants and funding